Prediction of Anticancer Drug Potency from Expression of Genes Involved in Growth Factor Signaling

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2006 Jan 21

PMID 16425089

Citations 7

Authors

Zunyan Dai

Catalin Barbacioru

Ying Huang

Wolfgang Sadee

Affiliations

Soon will be listed here.

Abstract

Purpose: This study develops and evaluates a systematic approach to finding biomarker genes for predicting potency of anticancer drugs against tumor cells, focusing on gene families related to growth factor signaling.

Methods: Cytotoxic potencies of 119 drugs against 60 neoplastic cell lines (NCI-60) were correlated with expression of 343 genes, including 90 growth factors and receptors, 63 metalloproteinases, and 92 ras-like GTPases as downstream signaling factors. Progressively more stringent criteria and predictive models aim at identifying the smallest subset of genes predictive of cytotoxic potency.

Results: Comparing gene expression with drug potency across the NCI-60 yielded genes with negative and positive correlations (p < 0.001), indicative of a role in chemoresistance and chemosensitivity, respectively. Of 17 genes with multiple negative correlations, 8 are known chemoresistance factors, validating the approach. Negatively correlated genes clustered into two main groups with distinct expression profiles and drug correlations, represented by EGFR and ERBB2 (Her-2/Neu). Accordingly, no synergism was observed between EGFR and ERBB2 inhibitors. However, combinations with classical anticacer drugs were not correlated with EGFR and ERBB2 expression in four cell lines tested, suggesting complex interactions in combination treatments. Finally, a subset of only 13 genes was found to be sufficient for near optimal prediction of drug potency against the NCI-60.

Conclusions: Our approach using a small subset of genes reveals known and potential biomarkers in cancer chemotherapy, providing a strategy for genome-wide analysis.

Citing Articles

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.

Gautam P, Karhinen L, Szwajda A, Kumar Jha S, Yadav B, Aittokallio T Mol Cancer. 2016; 15(1):34.

PMID: 27165605 PMC: 4862054. DOI: 10.1186/s12943-016-0517-3.

miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy.

Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang Y Tumour Biol. 2014; 35(7):7025-34.

PMID: 24752578 DOI: 10.1007/s13277-014-1965-2.

Therapeutic target database update 2014: a resource for targeted therapeutics.

Qin C, Zhang C, Zhu F, Xu F, Chen S, Zhang P Nucleic Acids Res. 2013; 42(Database issue):D1118-23.

PMID: 24265219 PMC: 3964951. DOI: 10.1093/nar/gkt1129.

Modulation of MicroRNAs by Chemical Carcinogens and Anticancer Drugs in Human Cancer: Potential Inkling to Therapeutic Advantage.

Haldar S, Basu A Mol Cell Pharmacol. 2012; 3(3):135-141.

PMID: 22288002 PMC: 3266367.

MicroRNA-375 and MicroRNA-221: Potential Noncoding RNAs Associated with Antiproliferative Activity of Benzyl Isothiocyanate in Pancreatic Cancer.

Basu A, Alder H, Khiyami A, Leahy P, Croce C, Haldar S Genes Cancer. 2011; 2(2):108-19.

PMID: 21779484 PMC: 3111247. DOI: 10.1177/1947601911409212.

References

Sirotnak F, Zakowski M, Miller V, Scher H, Kris M . Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2001; 6(12):4885-92. View

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D . New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82(13):1107-12. DOI: 10.1093/jnci/82.13.1107. View

Nahta R, Esteva F . HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res. 2003; 9(14):5078-84. View

Navolanic P, Steelman L, McCubrey J . EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol. 2003; 22(2):237-52. View

Murphy G, Graham S, Morita S, Reks S, Vojtek A, Kelley G . Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation. J Biol Chem. 2002; 277(12):9966-75. DOI: 10.1074/jbc.M109059200. View

Clark E, Golub T, Lander E, Hynes R . Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000; 406(6795):532-5. DOI: 10.1038/35020106. View

Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

Dai Z, Huang Y, Sadee W . Growth factor signaling and resistance to cancer chemotherapy. Curr Top Med Chem. 2004; 4(13):1347-56. DOI: 10.2174/1568026043387746. View

Winick N, Carroll W, Hunger S . Childhood leukemia--new advances and challenges. N Engl J Med. 2004; 351(6):601-3. DOI: 10.1056/NEJMe048154. View

10.

Yu D, Hung M . Role of erbB2 in breast cancer chemosensitivity. Bioessays. 2000; 22(7):673-80. DOI: 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A. View

11.

Sawyers C . Targeted cancer therapy. Nature. 2004; 432(7015):294-7. DOI: 10.1038/nature03095. View

12.

Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L . HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003; 22(21):3205-12. DOI: 10.1038/sj.onc.1206394. View

13.

Weinstein J, Kohn K, Grever M, Viswanadhan V, Rubinstein L, Monks A . Neural computing in cancer drug development: predicting mechanism of action. Science. 1992; 258(5081):447-51. DOI: 10.1126/science.1411538. View

14.

Brown C, Boyer A, Runyan R, BARNETT J . Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. Science. 1999; 283(5410):2080-2. DOI: 10.1126/science.283.5410.2080. View

15.

Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S . Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000; 6(5):2053-63. View

16.

Weinstein J, Myers T, OConnor P, Friend S, Fornace Jr A, Kohn K . An information-intensive approach to the molecular pharmacology of cancer. Science. 1997; 275(5298):343-9. DOI: 10.1126/science.275.5298.343. View

17.

Grutzmann R, Luttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I . ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer. 2004; 90(5):1053-8. PMC: 2409625. DOI: 10.1038/sj.bjc.6601645. View

18.

Nebert D, Vesell E . Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol. 2004; 500(1-3):267-80. DOI: 10.1016/j.ejphar.2004.07.031. View

19.

Staunton J, Slonim D, Coller H, Tamayo P, Angelo M, Park J . Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A. 2001; 98(19):10787-92. PMC: 58553. DOI: 10.1073/pnas.191368598. View

20.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View